Exact Therapeutics AS

Exact Therapeutics AS EBIT/Assets

The Operating Income to Assets Ratio (EBIT/Assets) of Exact Therapeutics AS (EXTX.OL) as of Oct 17, 2026 is -125.94 %. In the previous year, Operating Income to Assets Ratio (EBIT/Assets) was -34.50 % — a change of 265.03% (lower).

EBIT/Assets

-125.94 %

YoY

265.03%

Last updated:

Operating Income to Assets Ratio (EBIT/Assets) of Exact Therapeutics AS is 2025 -125.94 % . Operating Income to Assets Ratio (EBIT/Assets) of Exact Therapeutics AS was 2024 -34.50 % . It decreases by 265.03% lower compared to the previous year.

The Exact Therapeutics AS EBIT/Assets history

  • 3 Years

  • 10 Years

  • 25 Years

  • Max

EBIT/Assets
Date
EBIT/Assets
Jan 1, 2018
-12.06 NOK
Jan 1, 2019
-30.68 NOK
Jan 1, 2020
-20.38 NOK
Jan 1, 2021
-50.25 NOK
Jan 1, 2022
-49.42 NOK
Jan 1, 2023
-78.90 NOK
Jan 1, 2024
-34.50 NOK
Jan 1, 2025
-125.94 NOK
The Exact Therapeutics AS EBIT/Assets history
YEAREBIT/AssetsYoY
-125.94 %+265.03%
-34.50 %-56.27%
-78.90 %+59.65%
-49.42 %-1.66%
-50.25 %+146.54%
-20.38 %-33.55%
-30.68 %+154.40%
-12.06 %-51.26%
-24.74 %—

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Exact Therapeutics AS Stock analysis

What does Exact Therapeutics AS do? Exact Therapeutics AS is a clinical stage biopharmaceutical company headquartered in Oslo, Norway, specializing in biotechnology within the Health Care sector. The company focuses on developing a novel platform for ultrasound-mediated therapeutic amplification, specifically targeting drug enhancement through ACT sonoporation. This technology aims to amplify the clinical utility of various therapeutic agents across cancer, infectious diseases, and neurological conditions. Listed on 14 July 2020, Exact Therapeutics operates with a team of eight employees. Exact Therapeutics AS is one of the most popular companies on Eulerpool.

Frequently Asked Questions about Exact Therapeutics AS stock

Operating Income to Assets Ratio (EBIT/Assets) of Exact Therapeutics AS is -125.94 % in 2025.

Operating Income to Assets Ratio (EBIT/Assets) of Exact Therapeutics AS changed from -34.50 % to -125.94 %, representing a 265.03% change. The value is lower than the previous year.

On Eulerpool you can find the complete historical development of Operating Income to Assets Ratio (EBIT/Assets) Exact Therapeutics AS since 2006 – with annual values, charts, and detailed analysis.

EBIT/Assets measures operating profitability relative to total assets, providing an unlevered view of asset efficiency that is comparable across capital structures.

A 'good' varies by industry and company stage. On Eulerpool, you can compare Operating Income to Assets Ratio (EBIT/Assets)'s Exact Therapeutics AS with sector peers and the industry average to assess whether it is attractive.

To evaluate Operating Income to Assets Ratio (EBIT/Assets)'s, it is essential to compare it with peers in the same industry and sector. On Eulerpool, you can find direct industry comparisons for Operating Income to Assets Ratio (EBIT/Assets).

Access this data via the Eulerpool API

100,000 free requests/mo · no credit card

Get Free API Key

Profitability — Exact Therapeutics AS

ROEROAROCEROICAsset TurnoverInventory TurnoverReceivables TurnoverDays Sales OutstandingDays Inventory OutstandingDays Payable OutstandingCash Conversion CycleCROICGross Profit/AssetsFixed Asset TurnoverEquity TurnoverWorking Capital TurnoverPayables TurnoverCapital IntensityReceivables/RevenueInventory/RevenueEBIT/Assets

All Key Metrics — Exact Therapeutics AS